London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Exactly Phil and there's real depth to this investment when you dig a little further. e.g. for those that are not aware our CEO Tim Mitchell is the inventor of Oblean® (cetilistat) which Takeda did a colloboration with from Norgine following the Alizyme Therapeutics deal. i.e. Takeda and the close knit pharma sector in which Sareum operate in will be fully aware of how good a scientist Tim Mitchell is. All eyes are now waiting on a 7 am RNS regarding the 1801 trial in Australia and then hopefully a partnership with a global pharma....
Good luck, Brighty
52 week high 150!
《90m shares free float.
Could really take off from this level.
Thank God, a new ramper. Give us all a break. Keep up the good work fella, don't stop til £10 at least.
52 week high 150!
And good to know that there is absolutely no need to issue a speeding ticket under any circumstances.
36-50p would appear to be very achievable in the short term
I also bought more - another £20K worth today.
B.
This has got to be one of the best buys on London Stock Exchange at the moment, no real bad news over last few years since Sierra but dropped 90%, can only go one way in my eyes, can't see us getting to mad Covid day rumour prices but still got to be a multi bagger from here again
Yes and don't forget the UKRI project that highlighted that our key asset, SDC-1801, was superior to Dexamethasone. In the same briefing dated 1 July 2021 Sareum also confirmed that SDC -1801 demonstrated a profile similar to JAK1/JAK2 inhibitor Baricitinib. That news took our share price on its run that summer to over 450p (post consolidation price: 9p+ in old money). If we get positive news from Oz in the next few days the re-rate over the summer might be just as epic as it was in 2021.
This will be 30-40p by the end of next week....
B.
Another top up hoping that's the last negative headline for the company and this will be a bargain.
Be fearful when others are greedy & be greedy when others are fearful
A reminder for all Sareum shareholders to keep your eyes firmly fixed on the patent expiry dates, such as:
* Merck MSD’s Keytruda from 2029
* J &J’s Stelara from 2026 (Big opportunity for SDC 1801 as a replacement for J&J's psoriasis Stelara treatment)
* Bristol Myers Squibb's Revlimid, Eliquis and Opdivoand from 2026
* Takeda's Entyvio’s patent expiration of 2026 etc
i.e. Patents expiring in the next 3-5 years in the pharma sector are worth billions.
We also know that in 4 combo trials with Adavosertib, Keytruda, Gemcitabine and Dexamethasone that the SAR data has been very very encouraging.
* WEE1 / Adavosertib (AZ) for the treatment of selected TP53 mutated cancers.
* Keytruda (Merck) with 100% regression of tumours after 21 days
* Gemcitabine (Eli Lilly) with positive safety and efficacy in anogenital cancer
Plus, we know that in combo with dexamethasone - and I quote - “The Sareum compound as a single agent was well tolerated and there was no change in tolerability when combined with dexamethasone”, quote from Tim Mitchell & Stephen Parker.
Good luck, Brighty
My top up, just before 1pm, is shown as a sell along with a great many others.
3 left on 19 and 2 on 20.
Not just on here, but buys below current mid price, ie. 18.50...eg. 18.42, show in red on L2.
Agree with that Luton The Edison report from last year sums it for me “We see the initiation of the Phase I study as a key catalyst for a potential re-rating” at the time the SP was 87.5p rising to 149.00p then the RF Fiasco which has completely decimated the SP since regardless of any positive RNS’s; 3 patents granted, SRA737 on-licensed and good progress of SDC-1801 through P1a. There is a huge disconnect in the current SP / MK Cap
Must be another RNS incoming shortly for RF requesting the next bulk or shares. Hopefully chopping another £200K off the bill
It is nothing worse than criminal that the SP has been walked down so far purely due to the uncertainty over the RF funding.
There is a lot of fuel left in the tank here and much further to go before any decent news evolves.
Another 850k RF shares gone late reported nice
Just dipped my toe in with 50K shares, although I think my buy is showing as a sell at 18.5
Seems to be getting stronger. 45% over 5 days. Do we have a leak?
Over 50% in a week you can see why some would cut and run. LTH's and those that believe in the what SAR has in the pipeline will expect to hold for a justified reward in the long term.
GLA
I can see why some are taking profit now that we arent that far off the 100% gain point on the offer shares.
Capital preservation is quite sensible thing to consider, especially as a lot of people, myself included, have been badly burned here by the ridiculous games played on the sp.
Having said that, I have no intention of selling any yet, I may consider it as we get near 30p
Been out this share a few years, are we hoping for a pick up in price? I have 20K spare to invest. Should this be my next good decision
It’s healthy to churn and burn shares; someone’s soaking them up....and plenty of transformative news due:
- RF Cleared
- P1a trail complete preliminary data
- SRA737 Licensee reveals
- P1 Full Data
- 2a non dilutive funding
- US 1801 Patent
- SRA737 Combination Trial
- License Deal
- Sareum T/O
What you won’t find right now is a TYK2 or CHK1 sat idly on a shelf both are hot assets right now clocks ticking DYOR / GLA
Just had a little £4300 top up coming up as a sell on here, such a bad platform for trade prices